vs
Emergent BioSolutions Inc.（EBS）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是Emergent BioSolutions Inc.的1.2倍（$179.7M vs $148.7M），Rocket Lab Corp净利率更高（-29.5% vs -36.7%，领先7.3%），Rocket Lab Corp同比增速更快（35.7% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
EBS vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.2倍
$148.7M
营收增速更快
RKLB
高出59.3%
-23.6%
净利率更高
RKLB
高出7.3%
-36.7%
自由现金流更多
EBS
多$188.0M
$-114.2M
两年增速更快
RKLB
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $179.7M |
| 净利润 | $-54.6M | $-52.9M |
| 毛利率 | 42.9% | 38.0% |
| 营业利润率 | -18.8% | -28.4% |
| 净利率 | -36.7% | -29.5% |
| 营收同比 | -23.6% | 35.7% |
| 净利润同比 | -74.4% | -1.1% |
| 每股收益（稀释后） | $-0.95 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRKLB
| Q4 25 | $148.7M | $179.7M | ||
| Q3 25 | $231.1M | $155.1M | ||
| Q2 25 | $140.9M | $144.5M | ||
| Q1 25 | $222.2M | $122.6M | ||
| Q4 24 | $194.7M | $132.4M | ||
| Q3 24 | $293.8M | $104.8M | ||
| Q2 24 | $254.7M | $106.3M | ||
| Q1 24 | $300.4M | $92.8M |
净利润EBSRKLB
| Q4 25 | $-54.6M | $-52.9M | ||
| Q3 25 | $51.2M | $-18.3M | ||
| Q2 25 | $-12.0M | $-66.4M | ||
| Q1 25 | $68.0M | $-60.6M | ||
| Q4 24 | $-31.3M | $-52.3M | ||
| Q3 24 | $114.8M | $-51.9M | ||
| Q2 24 | $-283.1M | $-41.6M | ||
| Q1 24 | $9.0M | $-44.3M |
毛利率EBSRKLB
| Q4 25 | 42.9% | 38.0% | ||
| Q3 25 | 62.8% | 37.0% | ||
| Q2 25 | 52.5% | 32.1% | ||
| Q1 25 | 60.2% | 28.8% | ||
| Q4 24 | 39.4% | 27.8% | ||
| Q3 24 | 54.9% | 26.7% | ||
| Q2 24 | -18.8% | 25.6% | ||
| Q1 24 | 49.2% | 26.1% |
营业利润率EBSRKLB
| Q4 25 | -18.8% | -28.4% | ||
| Q3 25 | 33.1% | -38.0% | ||
| Q2 25 | 1.1% | -41.3% | ||
| Q1 25 | 22.5% | -48.3% | ||
| Q4 24 | -4.9% | -38.9% | ||
| Q3 24 | 22.0% | -49.5% | ||
| Q2 24 | -79.9% | -40.7% | ||
| Q1 24 | 13.2% | -46.4% |
净利率EBSRKLB
| Q4 25 | -36.7% | -29.5% | ||
| Q3 25 | 22.2% | -11.8% | ||
| Q2 25 | -8.5% | -46.0% | ||
| Q1 25 | 30.6% | -49.5% | ||
| Q4 24 | -16.1% | -39.5% | ||
| Q3 24 | 39.1% | -49.6% | ||
| Q2 24 | -111.2% | -39.2% | ||
| Q1 24 | 3.0% | -47.7% |
每股收益（稀释后）EBSRKLB
| Q4 25 | $-0.95 | $-0.09 | ||
| Q3 25 | $0.91 | $-0.03 | ||
| Q2 25 | $-0.22 | $-0.13 | ||
| Q1 25 | $1.19 | $-0.12 | ||
| Q4 24 | $-0.45 | $-0.11 | ||
| Q3 24 | $2.06 | $-0.10 | ||
| Q2 24 | $-5.38 | $-0.08 | ||
| Q1 24 | $0.17 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $1.0B |
| 总债务越低越好 | $589.7M | $152.4M |
| 股东权益账面价值 | $522.6M | $1.7B |
| 总资产 | $1.3B | $2.3B |
| 负债/权益比越低杠杆越低 | 1.13× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资EBSRKLB
| Q4 25 | $205.4M | $1.0B | ||
| Q3 25 | $245.5M | $976.7M | ||
| Q2 25 | $267.3M | $688.1M | ||
| Q1 25 | $149.1M | $428.4M | ||
| Q4 24 | $99.5M | $419.0M | ||
| Q3 24 | $149.9M | $442.4M | ||
| Q2 24 | $69.7M | $496.8M | ||
| Q1 24 | $78.5M | $492.5M |
总债务EBSRKLB
| Q4 25 | $589.7M | $152.4M | ||
| Q3 25 | $693.1M | $347.0M | ||
| Q2 25 | $700.0M | $346.5M | ||
| Q1 25 | $700.0M | $345.9M | ||
| Q4 24 | $700.0M | $345.4M | ||
| Q3 24 | $700.8M | $61.2M | ||
| Q2 24 | $863.8M | $64.2M | ||
| Q1 24 | $909.2M | $66.8M |
股东权益EBSRKLB
| Q4 25 | $522.6M | $1.7B | ||
| Q3 25 | $582.5M | $1.3B | ||
| Q2 25 | $536.2M | $688.5M | ||
| Q1 25 | $552.7M | $431.3M | ||
| Q4 24 | $482.8M | $382.5M | ||
| Q3 24 | $508.4M | $419.8M | ||
| Q2 24 | $386.3M | $455.2M | ||
| Q1 24 | $663.9M | $478.9M |
总资产EBSRKLB
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.5B | $2.2B | ||
| Q2 25 | $1.4B | $1.6B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.8B | $1.2B |
负债/权益比EBSRKLB
| Q4 25 | 1.13× | 0.09× | ||
| Q3 25 | 1.19× | 0.27× | ||
| Q2 25 | 1.31× | 0.50× | ||
| Q1 25 | 1.27× | 0.80× | ||
| Q4 24 | 1.45× | 0.90× | ||
| Q3 24 | 1.38× | 0.15× | ||
| Q2 24 | 2.24× | 0.14× | ||
| Q1 24 | 1.37× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $-114.2M |
| 自由现金流率自由现金流/营收 | 49.6% | -63.6% |
| 资本支出强度资本支出/营收 | 2.6% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流EBSRKLB
| Q4 25 | $77.7M | $-64.5M | ||
| Q3 25 | $-2.3M | $-23.5M | ||
| Q2 25 | $106.4M | $-23.2M | ||
| Q1 25 | $-11.2M | $-54.2M | ||
| Q4 24 | $-79.9M | $-2.4M | ||
| Q3 24 | $153.7M | $-30.9M | ||
| Q2 24 | $47.5M | $-13.0M | ||
| Q1 24 | $-62.6M | $-2.6M |
自由现金流EBSRKLB
| Q4 25 | $73.8M | $-114.2M | ||
| Q3 25 | $-5.7M | $-69.4M | ||
| Q2 25 | $103.5M | $-55.3M | ||
| Q1 25 | $-14.8M | $-82.9M | ||
| Q4 24 | $-81.6M | $-23.9M | ||
| Q3 24 | $147.9M | $-41.9M | ||
| Q2 24 | $42.9M | $-28.3M | ||
| Q1 24 | $-73.4M | $-21.8M |
自由现金流率EBSRKLB
| Q4 25 | 49.6% | -63.6% | ||
| Q3 25 | -2.5% | -44.8% | ||
| Q2 25 | 73.5% | -38.3% | ||
| Q1 25 | -6.7% | -67.6% | ||
| Q4 24 | -41.9% | -18.1% | ||
| Q3 24 | 50.3% | -40.0% | ||
| Q2 24 | 16.8% | -26.7% | ||
| Q1 24 | -24.4% | -23.5% |
资本支出强度EBSRKLB
| Q4 25 | 2.6% | 27.6% | ||
| Q3 25 | 1.5% | 29.6% | ||
| Q2 25 | 2.1% | 22.2% | ||
| Q1 25 | 1.6% | 23.4% | ||
| Q4 24 | 0.9% | 16.3% | ||
| Q3 24 | 2.0% | 10.5% | ||
| Q2 24 | 1.8% | 14.4% | ||
| Q1 24 | 3.6% | 20.7% |
现金转化率EBSRKLB
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
